You are leaving

You have selected a link that will take you to a site maintained by a third party who is solely responsible
for its contents.

Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.

To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.


Our promising pipeline of
innovative product candidates are
designed to target and help resolve
serious unmet medical needs

Our Pipeline

Pushing the boundaries of breakthrough therapies


Ivonescimab (SMT112)
Summit is initiating development activities for SMT112 and will do so first in NSCLC indications.

Summit Research
Focused on innovations leveraging deep leadership expertise in discovery and advancement of novel platforms.



Ivonescimab is currently being investigated in Phase 3 clinical studies. Phase 1 and 2 have been completed by our partner Akeso.
This pipeline reflects studies that have been announced.
Ivonescimab is an investigational therapy that is not approved by any regulatory authority.